More Telix Pharmaceuticals Limited news
Telix Pharmaceuticals LimitedASX: TLX

Prostate Cancer Therapy FDA Meeting Update

Nov 24, 2020 at 10:42 PM EST · Issued by Telix Pharmaceuticals Limited

Filed with ASX · Nov 24, 2020 at 10:42 PM EST

On 6ix: 6ix.com/news/prostate-cancer-therapy-fda-meeting-update

Watch Telix Pharmaceuticals' latest call↗Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call↗

Telix Pharmaceuticals Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Telix Pharmaceuticals Limited on 6ix

Earlier from Telix Pharmaceuticals

  • NDA for Prostate Cancer Imaging accepted by US FDANov 23, 2020
  • Investor Briefing - Asia StrategyNov 2, 2020
  • Strategic Licence and Partnership for Greater China MarketNov 1, 2020
  • App 4C and Activities Report for September 2020 QuarterOct 29, 2020
  • FDA grants Orphan Drug Designation for glioma imaging agentOct 5, 2020

Later from Telix Pharmaceuticals

  • Telix Acquires TheraPharm GmbHNov 29, 2020
  • Acquisition of TheraPharm GmbH - Investor CallNov 29, 2020
  • Briefing for Investor call - TheraPharm GmbH AcquisitionNov 30, 2020
  • Telix and DuChemBio - South Korea PartnershipDec 2, 2020
  • ProstACT Phase III Study Clinical Development UpdateDec 2, 2020
All Telix Pharmaceuticals news releases↗

Follow Telix Pharmaceuticals into a list and get an email when it puts out news.

Follow Telix Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer